Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-cohort, Multi-center Phase II Clinical Study of Adebrelimab in Combination With SHR-A1811/SHR-A1904 and Chemotherapy or Adebrelimab in Combination With SHR-8068 as the Treatment in Subjects With Gastric or Gastroesophageal Junction Cancer

NCT07110571 is registered in ClinicalTrials.gov with Suzhou Suncadia Biopharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT07110571
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07110571 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-cohort, Multi-center Phase II Clinical Study of Adebrelimab in Combination With SHR-A1811/SHR-A1904 and Chemotherapy or Adebrelimab in Combination With SHR-8068 as the Treatment in Subjects With Gastric or Gastroesophageal Junction Cancer
Lead sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
August 28, 2025
Completion date
May 31, 2027
Enrollment
200 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, gastroesophageal-junction cancer